Page 83 - Read Online

Puoti. Hepatoma Res 2018;4:57 I http://dx.doi.org/10.20517/2394-5079.2018.67 Page 11 of 11

Gastroenterology 2017;152:142-56.
32. Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A.
Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63.
33. Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? J Hepatol 2018;8:326-34.
34. White DL, Kanwal F, El-Serag HB. Association Between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on
systematic review. Clin Gastroenterol Hepatol 2012;10:1342-59.
35. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns
of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. Liver Int 2015;35:2155-66.
36. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M. Association of nonalcoholic fatty liver disease (NAFLD) with
hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 2015;62:1723-30.
37. Sanyal A, Poklepovic A, Moyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med
Res Opin 2010;26:2183-91.
38. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to nonalcoholic
steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
39. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S,
Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo
M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L. MBOAT7 rs641738 variant and hepatocellular carcinoma in
noncirrhotic individuals. Sci Rep 2017;7:4492.
40. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, Alhaddad R, Alkhouri N. Characterization of
hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatol Int 2016;10:632-9.
41. Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: the new epidemic of the third millennium. Benign liver state or silent killer?
Eur J Intern Med 2017;46:1-5.
42. Joshi K, Kohli A, Manch R, Gish R. High risk or low risk for developing hepatocellular carcinoma? Clin Liver Dis 2016;20:563-80.
43. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet
1995;346:987-90.
44. Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. A meta-analysis of alcohol drinking and cancer risk. Br J Cancer 2001;85:1700-5.
45. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J; EASL Panel
of Experts on HCC. Clinical management of hepatocellular carcinoma. J Hepatol 2001;35:421-30.
46. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of
U.S. adults. N Engl J Med 2003;24:1625-38.
47. Santi V, Trevisani F, Gramenzi AL, Grignaschi A, Milici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M, Giannini
EG, Borzio F, Caturelli E, Chiaramonte M, Bernardi M; Italian liver cancer (ITA.LI.CA) group. Semiannual surveillance is superiore to
annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010;53:291-7.
48. Pignata S, Gallo C, Daniele B, Elba S, Giorgio A, Capuano G. Characteristics at presentation and outcome of hepatocellular carcinoma
(HCC) in the elderly. A study of the cancer of the liver Italian program (CLIP). Crit Rev Oncol Hematol 2006;59:243-9.
49. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L,
Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F; Italian Liver Cancer Group. Treatments for
hepatocellular carcinoma in elderly patients are as effective as in younger patients. Gut 2010;59:387-96.
50. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus
transplantation. Hepatology 1999;30:1434-40.
51. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C. Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation
predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60.
52. Tian YW, Shen Q, Jiang QF, Wang YX, Li K, Xue HZ. Decreased levels of miR-34a and miR-217 act as predictor biomarkers of aggressive
progression and poor prognosis in hepatocellular carcinoma. Minerva Med 2017;108:108-13.
53. Chaiteerakij R, BD, Roberts LF. Update on biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2015;13:237-45.
54. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X,
Bruix J. Unexpected early tumor recurrence in patients with hepatitis C virus - related hepatocellular carcinoma undergoing interferon-free
therapy: a note of caution. J Hepatol 2016;65:719-26.
55. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti
S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals. J Hepatol
2016;65:727-33.
56. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol
2016;65:663-5.
57. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-
acting antiviral agents. Gastroenterology 2017;153:996-1005.
58. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting
antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.